drugset / Trial / NCT06328179
Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.
Recruiting
34 enrolled
Huai'an First People's Hospital
The Affiliated Hospital of Xuzhou Medical University · collabThe First People's Hospital of Changzhou · collabZhenjiang First People's Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is a clinical trial aimed at evaluating the efficacy and safety of the VHEA（Venetoclax with Homoharringtonine，Etoposide，Cytarabine）regimen in the treatment of newly diagnosed and relapsed/refractory acute myeloid leukemia (AML) with MLL gene abnormalities. This study includes the induction and consolidation phases of AML treatment.
Timeline
- Start
- 2022-05-24
- Primary completion
- 2027-12-30
- Completion
- 2027-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytarabine | Small molecule | 100 mg/m2 | — |
| Subject | Etoposide | Small molecule | 0.1 g | — |
| Subject | Homoharringtonine | Small molecule | 2 mg/m2 | — |
| Subject | Venetoclax | Small molecule | 400 mg | — |